Short-term treatment of CIDP with efgartigimod: a case series in China
ObjectiveChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of autoimmune neuropathy with treatment challenges due to the limitations of standard of care therapies. Efgartigimod, a neonatal Fc receptor antagonist, has shown potential in treating antibody-mediated disorders in...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533167/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173316067753984 |
|---|---|
| author | Chong Sun Chong Sun Chong Sun Jianian Hu Jianian Hu Jianian Hu Yanyin Zhao Yanyin Zhao Yanyin Zhao Yongsheng Zheng Yongsheng Zheng Yongsheng Zheng Quanhua Meng Sushan Luo Sushan Luo Sushan Luo Kai Qiao Kai Qiao Kai Qiao Jian Sun Jian Sun Jian Sun Jiahong Lu Jiahong Lu Jiahong Lu Jie Lin Jie Lin Jie Lin Chongbo Zhao Chongbo Zhao Chongbo Zhao |
| author_facet | Chong Sun Chong Sun Chong Sun Jianian Hu Jianian Hu Jianian Hu Yanyin Zhao Yanyin Zhao Yanyin Zhao Yongsheng Zheng Yongsheng Zheng Yongsheng Zheng Quanhua Meng Sushan Luo Sushan Luo Sushan Luo Kai Qiao Kai Qiao Kai Qiao Jian Sun Jian Sun Jian Sun Jiahong Lu Jiahong Lu Jiahong Lu Jie Lin Jie Lin Jie Lin Chongbo Zhao Chongbo Zhao Chongbo Zhao |
| author_sort | Chong Sun |
| collection | DOAJ |
| description | ObjectiveChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of autoimmune neuropathy with treatment challenges due to the limitations of standard of care therapies. Efgartigimod, a neonatal Fc receptor antagonist, has shown potential in treating antibody-mediated disorders including CIDP (ADHERE study), but real-world studies on the application of efgartigimod in CIDP are still lacking. This study aimed to evaluate the short-term efficacy and safety of efgartigimod in five patients with CIDP in China.MethodsClinical effectiveness was assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale, Inflammatory Rasch-built Overall Disability Scale (IRODS), Medical Research Council (MRC) sum score (0–60), grip strength, Neuropathy Impairment Score (NIS), and 3-m Time Up and Go Test (TUG). Safety was evaluated by monitoring adverse events and measuring white blood cell count, serum albumin concentration, and plasma IgG concentration. Peripheral CD4+ T and CD19+ B lymphocytes were measured before and after efgartigimod treatment.ResultsAll five (100%) patients responded to efgartigimod treatment, with four (80%) meeting predefined effectiveness criteria within 8 weeks. The average reduction rate in total IgG was 43%. Adverse events were minimal, with one patient experiencing transient diarrhea, and no aggravation of pre-existing conditions was noted.InterpretationEfgartigimod demonstrates promising efficacy and safety for short-term treatment of CIDP, offering a potential alternative therapy. This study provides valuable evidence from the real-world application of efgartigimod in CIDP, and the results indicate further research is warranted. |
| format | Article |
| id | doaj-art-9c233e203eaa4b519e8dd9a25d2f795c |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-9c233e203eaa4b519e8dd9a25d2f795c2025-08-20T02:19:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15331671533167Short-term treatment of CIDP with efgartigimod: a case series in ChinaChong Sun0Chong Sun1Chong Sun2Jianian Hu3Jianian Hu4Jianian Hu5Yanyin Zhao6Yanyin Zhao7Yanyin Zhao8Yongsheng Zheng9Yongsheng Zheng10Yongsheng Zheng11Quanhua Meng12Sushan Luo13Sushan Luo14Sushan Luo15Kai Qiao16Kai Qiao17Kai Qiao18Jian Sun19Jian Sun20Jian Sun21Jiahong Lu22Jiahong Lu23Jiahong Lu24Jie Lin25Jie Lin26Jie Lin27Chongbo Zhao28Chongbo Zhao29Chongbo Zhao30Department of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaPeople’s Hospital of Deyang City, Deyang, Sichuan, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, ChinaNational Center for Neurological Disorders, Fudan University, Shanghai, ChinaHuashan Rare Disease Center, Shanghai Medical College, Fudan University, Shanghai, ChinaObjectiveChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of autoimmune neuropathy with treatment challenges due to the limitations of standard of care therapies. Efgartigimod, a neonatal Fc receptor antagonist, has shown potential in treating antibody-mediated disorders including CIDP (ADHERE study), but real-world studies on the application of efgartigimod in CIDP are still lacking. This study aimed to evaluate the short-term efficacy and safety of efgartigimod in five patients with CIDP in China.MethodsClinical effectiveness was assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale, Inflammatory Rasch-built Overall Disability Scale (IRODS), Medical Research Council (MRC) sum score (0–60), grip strength, Neuropathy Impairment Score (NIS), and 3-m Time Up and Go Test (TUG). Safety was evaluated by monitoring adverse events and measuring white blood cell count, serum albumin concentration, and plasma IgG concentration. Peripheral CD4+ T and CD19+ B lymphocytes were measured before and after efgartigimod treatment.ResultsAll five (100%) patients responded to efgartigimod treatment, with four (80%) meeting predefined effectiveness criteria within 8 weeks. The average reduction rate in total IgG was 43%. Adverse events were minimal, with one patient experiencing transient diarrhea, and no aggravation of pre-existing conditions was noted.InterpretationEfgartigimod demonstrates promising efficacy and safety for short-term treatment of CIDP, offering a potential alternative therapy. This study provides valuable evidence from the real-world application of efgartigimod in CIDP, and the results indicate further research is warranted.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533167/fullchronic inflammatory demyelinating polyradiculoneuropathy (CIDP)efgartigimodshort-termtreatmentreal-world studyChina |
| spellingShingle | Chong Sun Chong Sun Chong Sun Jianian Hu Jianian Hu Jianian Hu Yanyin Zhao Yanyin Zhao Yanyin Zhao Yongsheng Zheng Yongsheng Zheng Yongsheng Zheng Quanhua Meng Sushan Luo Sushan Luo Sushan Luo Kai Qiao Kai Qiao Kai Qiao Jian Sun Jian Sun Jian Sun Jiahong Lu Jiahong Lu Jiahong Lu Jie Lin Jie Lin Jie Lin Chongbo Zhao Chongbo Zhao Chongbo Zhao Short-term treatment of CIDP with efgartigimod: a case series in China Frontiers in Immunology chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) efgartigimod short-term treatment real-world study China |
| title | Short-term treatment of CIDP with efgartigimod: a case series in China |
| title_full | Short-term treatment of CIDP with efgartigimod: a case series in China |
| title_fullStr | Short-term treatment of CIDP with efgartigimod: a case series in China |
| title_full_unstemmed | Short-term treatment of CIDP with efgartigimod: a case series in China |
| title_short | Short-term treatment of CIDP with efgartigimod: a case series in China |
| title_sort | short term treatment of cidp with efgartigimod a case series in china |
| topic | chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) efgartigimod short-term treatment real-world study China |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533167/full |
| work_keys_str_mv | AT chongsun shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT chongsun shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT chongsun shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jianianhu shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jianianhu shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jianianhu shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT yanyinzhao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT yanyinzhao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT yanyinzhao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT yongshengzheng shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT yongshengzheng shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT yongshengzheng shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT quanhuameng shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT sushanluo shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT sushanluo shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT sushanluo shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT kaiqiao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT kaiqiao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT kaiqiao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jiansun shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jiansun shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jiansun shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jiahonglu shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jiahonglu shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jiahonglu shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jielin shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jielin shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT jielin shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT chongbozhao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT chongbozhao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina AT chongbozhao shorttermtreatmentofcidpwithefgartigimodacaseseriesinchina |